Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Insights from the EVEREST Trial
Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Insights from the EVEREST Trial
复制标题
DOI：
10.1161/circheartfailure.112.970525
复制
发表时间：
2012-11-01
影响因子：
9.7
通讯作者：
Gheorghiade, Mihai
中科院分区：
文献类型：
--
作者：
Vaduganathan, Muthiah;Ambrosy, Andrew P.;Gheorghiade, Mihai
背景-低淋巴细胞计数已被证明是门诊心力衰竭（HF）的独立预后标志。关于相对淋巴细胞计数是否与因心力衰竭住院的患者出院后结果相关的数据有限。方法和结果 - 我们利用托伐普坦 (EVEREST) 试验对心力衰竭结果研究中加压素拮抗剂的功效进行了事后分析，该试验对 4133 名因射血分数恶化的心力衰竭住院患者进行了随机分组
Background-Low lymphocyte count has been shown to be an independent prognostic marker in heart failure (HF) in the outpatient setting. Limited data exist regarding whether relative lymphocyte count correlates with postdischarge outcomes in patients hospitalized for HF.Methods and Results-We performed a post hoc analysis of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial, which randomized 4133 patients hospitalized for worsening HF with an ejection fraction